First-in-India: Johnson & Johnson Receives Approval for VARIPULSE™ Platform, Advancing Atrial Fibrillation Treatment

First-in-India: Johnson & Johnson Receives Approval for VARIPULSE™ Platform, Advancing Atrial Fibrillation Treatment

Get latest articles and stories on Business at LatestLY. Mumbai (Maharashtra) [India], June 3: Johnson & Johnson* today announced the approval of the VARIPULSE™ Platform, India's first Pulsed Field Ablation (PFA) technology that has been used to perform catheter ablation procedures for atrial fibrillation (AFib) in more than 80,000 procedures globally.2 AFib is an irregular and often rapid heartbeat caused by extra, uncoordinated electrical sign…

First-in-India: Johnson & Johnson Receives Approval for VARIPULSE Platform, Advancing Atrial Fibrillation Treatment

Johnson & Johnson* today announced the approval of the VARIPULSE Platform, India's first Pulsed Field Ablation (PFA) technology that has been used to perform catheter ablation procedures for atrial fibrillation (AFib) in more than 80,000 procedures globally.2 AFib is an irregular and often rapid heartbeat caused by extra, uncoordinated electrical signals in the atria and is associated with structural changes in the heart due to underlying conditions and lifestyle factors.x, xi It significantly increases the risk of stroke, heart failure, and mortality. Atrial Fibrillation affects 50 million people worldwide,xii representing a burden comparable to heart failure, which impacts over 64 million people globally.xiii In India, AFib prevalence is estimated at 0.1% to 1.6% of the population, with approximately 5 million people currently living with the condition.xiv, xv, xvi Indian patients develop AFib nearly a decade earlier than those in Western populations, at an average age of around 55 years, extending the long-term disease burden.xvii, xviii Underlying AFib in India is detected at the time of stroke in 20-45% of cases.xix As a progressive condition, early intervention in AFib is critical to reducing stroke risk, particularly given that India accounted for 773,000 stroke deaths in 2021, or 10% of global stroke deaths.xx Catheter ablation is a minimally invasive procedure used to restore normal heart rhythm by treating areas responsible for abnormal electrical signals. PFA is a catheter ablation technique that uses short, high-voltage electrical pulses to target cardiac cells by creating pores in cell membranes, leading to cell death. It has the potential to offer safe, consistent, and efficient therapy for AFib treatment.xxi The VARIPULSE Platform is the first PFA technology designed to streamline ablation and mapping through a single integrated workflow with the CARTO 3 System. This 3D electroanatomical cardiac mapping technology enables real-time visualization and supports precision, efficiency, reproducibility, and procedural accuracy for physicians treating patients with atrial fibrillation (AFib).xxii It enables safe and efficient i,ii, iii, iv,v, vi,vii patient-centric therapy with minimal to no fluoroscopy exposure xxiii,xxiv, xxv and is compatible with deep and/or conscious sedation.3, xxvi, xxvii "The approval of the VARIPULSE Platform in India marks an important milestone in advancing AFib treatment," said Randeep Sharma, General Manager, India, Electrophysiology, MedTech, Johnson & Johnson. "Pulsed field ablation is gaining momentum globally, and bringing an integrated platform like VARIPULSE to India will enable physicians to deliver more precise and efficient care for AFib patients." The innovation is backed by compelling clinical evidence with the most recent real-world evidence demonstrating strong safety and effectiveness of the VARIPULSE Platform

Johnson & Johnson launches VARIPULSE platform for AFib treatment in India

Johnson & Johnson has announced the approval of the VARIPULSE Platform, a Pulsed Field Ablation (PFA) technology in India for catheter ablation procedures in patients with atrial fibrillation (AFib). According to the company, the platform has been used in more than 80,000 catheter ablation procedures globally. Atrial fibrillation is an irregular and often rapid heartbeat caused by extra, uncoordinated electrical signals in the atria. The conditi…